Control study of camrelizumab combined with albumin-bound paclitaxel in senile advanced triple-negative breast cancer
Objective To explore the clinical effectiveness of camrelizumab plus albumin-bound paclitaxelin in the treatment of senile advanced triple-negative breast cancer(TNBC).Methods Eighty elderly patients with advanced TNBC were divided into observation and control group according to patients'will to treatment,with 40 ones in each.Controls received albumin-bound paclitaxelin treatment and observation group was plus camrelizumab on the basis of controls,21 days were a treatment cycle,and both groups were continuously treated for 6 cycles.Such indexes were compared between two groups as clinical effectiveness,occurrence of toxic and side effect,survival rates within 1 year as well as pre-and post-treatment serum markers(carcinoembryonic antigen[CEA],carbohydrate antigen 153[CA153],vascular endothelial growth factor[VEGF])levels and quality of life(Functional Assessment of Cancer Therapy-B[FACT-B]scores).Results The disease control rate was higher in observation than control group and difference statistically significant(P＜0.05).After treatment,serum CEA,CA153 and VEGF level were lower and the total,physiological,emotional and functional status score of the FACT-B higher in observation than control group(P＜0.01).Intergroup differences in the occurrence of toxic and side effects such as myelosuppression,nausea and vomiting,cardiotoxicity,and abnormal liver and renal functions weren't statistically significant(P＞0.05).Intergroup difference in survival rate within 1 year wasn't statistically significant(P＞0.05).Conclusion Camrelizumab plus albumin-bound paclitaxel has better curative effect in senile advanced TNBC,can effectively reduce the levels of serum tumor markers,improve patients'quality of life,and doesn't increase toxic and side effects.
triple-negative breast cancercamreli-zumabalbumin-bound paclitaxelserum tumor marker
万方数据
维普
